Expression Analyses of Epidermal Growth Factor Receptor and HER-2/neu: No Advantage of Prediction of Recurrence or Survival in Breast Cancer Patients

Oncology ◽  
1996 ◽  
Vol 53 (6) ◽  
pp. 441-447 ◽  
Author(s):  
Matthias W. Beckmann ◽  
Dieter Niederacher ◽  
Gero Massenkeil ◽  
Boris Tutschek ◽  
Andreas Beckmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cancer Patients ◽  
Growth Factor Receptor ◽  
Breast Cancer Patients ◽  
Her 2 ◽  
Epidermal Growth

scholarly journals Human epidermal growth factor receptor 2/neu and the clinico-pathological profile in breast cancer: an observational study at a tertiary care hospital in Central India

2021 ◽  
Vol 8 (12) ◽  
pp. 3649
Author(s):  
Shikha Shukla ◽  
Fahad Ansari
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Breast Carcinoma ◽  
Epidermal Growth Factor ◽  
Cancer Patients ◽  
Growth Factor Receptor ◽  
Breast Cancer Patients ◽  
Her 2 ◽  
Epidermal Growth

Background: Breast cancer is the most commonly occurring cancer in women and the second most common cancer overall. Owing to a unique pattern of presentation in terms of clinical and biological features, finding their mutual association may be important and may help predict prognosis. HER2 (human epidermal growth factor receptor 2)/neu is one such important immunohistochemical factor that is considered to be more prevalent amongst Indians and therefore makes up for an emerging area for studies. The study aimed to assess the patients of breast carcinoma in terms of their HER2/neu statuses and find out their association with clinical parameters.Methods: This was a prospective comparative study conducted in department of surgery, Hamidia hospital, Bhopal, India, with a total duration of 1 year between November 2018 to September 2019 including a total of 98 consecutive in house breast carcinoma patients.Results: A total of 98 breast cancer patients were tested for HER-2/neu gene presence. Of these 25 (25.5%) samples tested positive and 73 (7.48%) tested negative. A comparison of the two groups revealed that none of the clinic-pathological factors tested were found to have a statistically significant association with the HER2/neu status.Conclusions: It appeared that there is no defining factor in terms of clinic-pathological presentation that helps to separate significantly HER-2/neu positive with HER-2/neu negative cases with breast cancer. Still, immune-histochemical marker analysis should be an integral part of the overall work up of the breast cancer patients because of its both prognostic and therapeutic application and significance.

scholarly journals Controversies of radiotherapy in human epidermal growth factor receptor (HER)-2 positive breast cancer patients

2021 ◽  
Vol 165 (1) ◽  
pp. 19-25
Author(s):  
Iveta Kolarova ◽  
Bohuslav Melichar ◽  
Jaroslav Vanasek ◽  
Ales Ryska ◽  
Katerina Horackova ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cancer Patients ◽  
Growth Factor Receptor ◽  
Breast Cancer Patients ◽  
Her 2 ◽  
Epidermal Growth ◽  
Positive Breast Cancer

scholarly journals Relations of Human Epidermal Growth Factor Receptor 2 (HER2) Expression and E-Cadherin (CDH1) Expression in Breast Cancer Patients

Biomedika ◽  
2021 ◽  
Vol 14 (1) ◽  
pp. 1-8
Author(s):  
Martga Bella Rahimi ◽  
Wirsma Arif Harahap ◽  
Yanwirasti Yanwirasti
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cancer Patients ◽  
Growth Factor Receptor ◽  
Her2 Expression ◽  
Breast Cancer Patients ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth

The aim of this study is to analyze the relations of Human Epidermal Growth Factor Receptor 2 (HER2) expression and E-Cadherin (CDH1) expression in breast cancer patients. To date, the synergistic effect of this CDH1/HER2 complex is not well clarified. The design of this study was cross-sectional with a total sample of 56 formalin-fixed paraffin tissue blocks that had been examined for HER2. Furthermore, CDHI expression was examined using the Immunohistochemistry staining technique with the Labeled Streptavidin Biotin Complex (LSAB) method. Bivariate analysis was performed using the Spearman correlation test with abnormally distributed data (p>0.05). Of the 56 data on breast cancer patients, most of the patients (87.5%) were diagnosed at the age of ≥40 years. The majority of cancer staging was IIIB, which was 42.9% of the total 56 patients. The study results shows that 80.0% of HER2-positive patients were in the strong CDH1 group. From these data, there is evidence of correlation between HER2 expression and CDH1 expression in breast cancer patients, however this correlation was not significant (p>0.05).

Sign in / Sign up

Export Citation Format

Share Document